Warner-Lambert to reimburse qualifying patients for reimmunization following Fluogen recall.
Executive Summary
WARNER-LAMBERT TO REIMBURSE HIGH-RISK INDIVIDUALS FOR FLU REIMMUNIZATION following the company's recall of 11 lots of its Parke-Davis subsidiary's Fluogen trivalent influenza vaccine. FDA and the Centers for Disease Control Prevention advised health care professionals Dec. 17 that they may consider reimmunizing individuals at risk for flu who received the recalled vaccine.